Non-Operating Income/Expense (Annual)

Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.

Halozyme Therapeutics, Inc. (HALO) had Non-Operating Income/Expense of $-2.13M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$1.40B
Net Income	$316.89M
Cost of Goods Sold	$228.77M
Gross Profit	$1.17B
Operating Expenses	$927.60M
Operating Income	$469.01M
Non-Operating Income/Expense	$-2.13M
Pre-Tax Income	$466.88M
Normalized Pre-Tax Income	$466.88M
Income after Taxes	$316.89M
Income from Continuous Operations	$316.89M
Consolidated Net Income/Loss	$316.89M
Normalized Income after Taxes	$316.89M
EBIT	$469.01M
EBITDA	$561.27M
Weighted-Average Shares Outstanding (Basic)	119.84M
Weighted-Average Shares Outstanding (Diluted)	123.90M
Earnings per Share (EPS) (Basic)	$2.64
Earnings per Share (EPS) (Diluted)	$2.56
Balance Sheet Financials
Current Assets	$825.21M
Property, Plant, and Equipment	$82.14M
Long-Term Assets	$1.70B
Total Assets	$2.53B
Current Liabilities	$177.09M
Long-Term Debt	$2.14B
Long-Term Liabilities	$2.30B
Total Liabilities	$2.48B
Common Equity	$48.81M
Tangible Shareholders Equity	$-1.51B
Shareholders Equity	$48.81M
Common Shares Outstanding	117.78M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$651.56M
Cash Flow from Investing Activities	$-545.81M
Cash Flow from Financial Activities	$-85.17M
Beginning Cash	$115.85M
End Cash	$136.42M
Increase/Decrease in Cash	$20.57M
Stock-Based Compensation	$51.56M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.66
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.98
Debt to Equity Ratio	43.89
Gross Margin	83.62%
Operating Margin	33.58%
EBIT Margin	33.58%
EBITDA Margin	40.19%
Pre-Tax Profit Margin	33.43%
Profit Margin	22.69%
Free Cash Flow	$644.59M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.55
Inventory Turnover	1.30
Receiveable Turnover	3.17
Days Sales in Receivables	115.33
Return on Equity	649.18%
Return on Tangible Equity	-20.94%
Return on Assets	12.55%
Return on Investments	14.46%
Book Value Per Share	$0.41
Free Cash Flow per Share	$5.20
Operating Cash Flow per Share	$5.26

Data from Zacks Investment Research, Inc.